EU Parliamentarians clashed notably during the SANT committee debate on 19 March 2026 over how to structure EU action on rare diseases and health prevention. The primary divide was between supporters of a legally binding European regulation and stronger data infrastructure championed by Nicolás González Casares (S&D) and Billy Kelleher (Renew), versus those favoring coordination through existing instruments and respect for Member States' competences, represented by Donata Meroni (European Commission), Elena Nevado Del Campo (EPP), and Margarita De La Pisa Carrión (PfE).
The debate took place within the context of an own-initiative report on an EU rare disease action plan and a discussion of a STOA exposome study, highlighting the need for prevention-driven health policy. Crucially, Roel Vermeulen (Utrecht University), joined by members like Stine Bosse (Renew), pushed the novel concept of the exposome—integrating chemical, social, and biological exposures—as a means to shift focus from disease management to prevention, calling for dedicated EU infrastructures and a prevention pillar.
González Casares proposed concrete measures such as a European regulation to unify incentives across Member States, updated national rare disease plans with measurable targets, faster diagnosis (advocating a one-year limit), interoperable data layers within the European Health Data Space, and enhanced funding and training. These targets would raise the powers of EU health institutions, increase data transparency, and impose more stringent governance on national health systems.
Conversely, the Commission’s Donata Meroni stressed ongoing initiatives like the Critical Medicines Act and cross-border healthcare directives, proposing coordination rather than new regulations. She and others urged respect for national sovereignty, citing legal and technical feasibility concerns. They sought to strengthen European Reference Networks without overruling Member States and advocated leveraging existing funding mechanisms and regulatory tools without expanding EU powers decisively.
This cleavage embodies the classic integration vs. sovereignty and regulation vs. coordination tension. For rare disease patients and families – deeply affected by fragmented diagnosis and access – González Casares and Kelleher's approach offers more rapid harmonization and improved access but may increase compliance costs for national authorities and pharmaceutical firms. The Commission’s approach poses less regulatory burden but risks perpetuating uneven care and slower diagnosis.
On prevention, Vermeulen's exposome framework envisages an expanded EU science-policy interface and funding for complex environmental and social data integration, promising better understanding of disease drivers with cross-sector gains for urban planners and public health authorities. Yet, as Margarita De La Pisa Carrión cautioned, this research is costly, with uncertain returns, and risks public anxiety without clear policy follow-through.
The debate signals a forthcoming intense legislative phase where Parliament will balance ambitions for EU-wide rare disease and prevention strategies against practical constraints and Member State prerogatives. Amendments to the rare disease report were anticipated by 26 March 2026, with the potential to influence Commission actions and future funding priorities, marking a critical moment in EU health policymaking.